SavedAdd your journal

Journals / Turkish Journal of Biology / 2021 / Cilt: 45 - Sayı: 1

The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells

Vildan BOZOK ÇETİNTAŞ
Zekeriya DÜZGÜN
Eda DOĞAN
Zafer YILDIRIM
Berrin ÖZDİL
Hüseyin AKTUĞ
Pages
26–34
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Understanding the mechanisms of PIKfyve inhibitors may improve cancer treatment particularly for EGFR overactivated NSCLC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:PIKfyve is an evolutionarily conserved lipid and protein kinase enzyme that has pleiotropic cellular functions.
📊
Key Findings & Data:The aim of the present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) inhibitor, YM201636, on nonsmall cell lung cancer (NSCLC) cells growth, tumorigenicity, and claudin (CLDN) expressions.
💡
Conclusion & Impact:Understanding the mechanisms of PIKfyve inhibitors may improve cancer treatment particularly for EGFR overactivated NSCLC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

PIKfyve is an evolutionarily conserved lipid and protein kinase enzyme that has pleiotropic cellular functions. The aim of the present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) inhibitor, YM201636, on nonsmall cell lung cancer (NSCLC) cells growth, tumorigenicity, and claudin (CLDN) expressions. Three NSCLC cell lines (Calu-1, H1299 and HCC827) were used to compare the effects of YM201636. Cytotoxic effects of YM201636 were analysed using XTT assay. Malignancy potential of cells assesses with wound healing and soft agar colony-forming assays. mRNA and protein expressions of claudins were analysed by qRT-PCR and immunofluorescence staining. Our results revealed that YM201636 inhibited the proliferation and malignancy potential of Calu-1, H1299, and HCC827 cells in a dose-dependent manner. After YM201636 treatment CLDN1, -3 and -5 expressions increased significantly in HCC827 cells. CLDN3 and -5 expressions also significantly increased in Calu-1 cell line. YM201636 treatment significantly reduced the CLDN1 and increased the CLDN5 expression in H1299 cells. Immunofluorescence staining of CLDN1, -3 and -5 proteins showed a significant increase after YM201636 treatment. Besides, YM201636 induced EGFR mRNA expression in all NSCLC cell lines. Our results have shown that YM201636 inhibits tumorigenicity of NSCLC cells. Furthermore, estimated glomerular filtration rate (EGFR) pathway is important signalling involved in the regulation of claudins. Understanding the mechanisms of PIKfyve inhibitors may improve cancer treatment particularly for EGFR overactivated NSCLC.

🔖

Cite This Article

ÇETİNTAŞ, V. B., DÜZGÜN, Z., DOĞAN, E., YILDIRIM, Z., ÖZDİL, B., AKTUĞ, H. (2022). The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells. Turkish Journal of Biology, Cilt: 45 - Sayı: 1, 26–34. https://ajindex.com/articles/600139

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. de Campos CB, Zhu YX, Sepetov N, Romanov S, Bruins LA et al. (2020). Identification of PIKfyve kinase as a target in multiple myeloma. Haematologica 105: 1641-1649.
  2. Dukes JD, Whitley P, Chalmers AD (2012). The PIKfyve inhibitor YM201636 blocks the continuous recycling of the tight junction proteins claudin-1 and claudin-2 in MDCK cells. PLoS One 7:e28659. Fang H, Wang Y, Xu L, Zhou S, Bai J et al. (2019). EGFR inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins. International Journal of Molecular Medicine 43: 1522-1530.
  3. Hou JZ, Xi ZQ, Niu J, Li W, Wang X, et al. (2019). Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy. Oncology Reports 41:1971- 1979.
  4. Hung CY, Yang WB, Wang SA, Hsu TI, Chang WC, et al. (2014). Nucleolin enhances internal ribosomal entry site (IRES)- mediated translation of Sp1 in tumorigenesis. Biochimica et Biophysica Acta 1843:2843-2854.
  5. Ikonomov OC, Altankov G, Sbrissa D, Shisheva A (2018). PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation. Toxicology and Applied Pharmacology 356: 151-158.
  6. Ikonomov OC, Sbrissa D, Shisheva A (2006). Localized PtdIns 3,5- P2 synthesis to regulate early endosome dynamics and fusion. American Journal of Physiology-Cell Physiology 291: C393- 404. J efferies HB, Cooke FT, Jat P, Boucheron C, Koizumi T et al. (2008). A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding. EMBO Reports 9: 164-170.
  7. Khan N, Asif AR (2015). Transcriptional regulators of claudins in epithelial tight junctions. Mediators of Inflammation 2015: 219843. Kim H, Kim SH, Hwang D, An J, Chung HS, et al. (2020). Extracellular pyruvate kinase M2 facilitates cell migration by upregulating claudin-1 expression in colon cancer cells. Biochemistry and Cell Biology 98: 219-226.
  8. Kim J, Jahng WJ, Di Vizio D, Lee JS, Jhaveri R et al. (2007). The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Research 67: 9229-9237.
  9. Krause G, Winkler L, Piehl C, Blasig I, Piontek J et al. (2009). Structure and function of extracellular claudin domains. Annals of the New York Academy of Sciences 1165: 34-43.
  10. Ma L, Yin W, Ma H, Elshoura I, Wang L (2019). Targeting claudin-3 suppresses stem cell-like phenotype in nonsquamous nonsmall-cell lung carcinoma. Lung Cancer